Art. -Nr.: HY-W008870

MTOA-TFSI

Kundenbewertung

Based on 1 Customer Validation

MTOA-TFSI is an ionic liquid with high porosity and conductivity, which can be used in electrochemical mechanical strain (ECMS) studies.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 375395-33-8
Formel: C₂₇H₅₄F₆N₂O₄S₂
Molecular Weight:648.85

Speicherung:

Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

MTOA-TFSI Chemical Structure

CAS. Nr.: 375395-33-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

MTOA-TFSI is an ionic liquid with high porosity and conductivity, which can be used in electrochemical mechanical strain (ECMS) studies^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	GI₅₀	0.415 μM Compound: 5, NSC-747259	Growth inhibition of human 786-0 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human 786-0 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
A498	GI₅₀	1.82 μM Compound: 5, NSC-747259	Growth inhibition of human A498 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human A498 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
A549	GI₅₀	1.9 μM Compound: 5, NSC-747259	Growth inhibition of human A549 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human A549 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
ACHN	GI₅₀	0.63 μM Compound: 5, NSC-747259	Growth inhibition of human ACHN cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human ACHN cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
BT-549	GI₅₀	0.421 μM Compound: 5, NSC-747259	Growth inhibition of human BT549 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human BT549 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
CCRF-CEM	GI₅₀	0.19 μM Compound: 5, NSC-747259	Growth inhibition of human CCRF-CEM cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human CCRF-CEM cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
COLO 205	GI₅₀	0.292 μM Compound: 5, NSC-747259	Growth inhibition of human COLO205 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human COLO205 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
DU-145	GI₅₀	0.407 μM Compound: 5, NSC-747259	Growth inhibition of human DU145 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human DU145 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
EKVX	GI₅₀	0.215 μM Compound: 5, NSC-747259	Growth inhibition of human EKVX cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human EKVX cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
HCC 2998	GI₅₀	0.425 μM Compound: 5, NSC-747259	Growth inhibition of human HCC2998 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human HCC2998 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
HCT-116	GI₅₀	0.319 μM Compound: 5, NSC-747259	Growth inhibition of human HCT116 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human HCT116 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
HCT-15	GI₅₀	0.993 μM Compound: 5, NSC-747259	Growth inhibition of human HCT15 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human HCT15 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
HL-60(TB)	GI₅₀	0.173 μM Compound: 5, NSC-747259	Growth inhibition of human HL-60(TB) cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human HL-60(TB) cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
HOP-62	GI₅₀	0.787 μM Compound: 5, NSC-747259	Growth inhibition of human HOP62 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human HOP62 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
HOP-92	GI₅₀	0.206 μM Compound: 5, NSC-747259	Growth inhibition of human HOP92 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human HOP92 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
Hs-578T	GI₅₀	0.417 μM Compound: 5, NSC-747259	Growth inhibition of human Hs 578T cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human Hs 578T cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
HT-29	GI₅₀	0.305 μM Compound: 5, NSC-747259	Growth inhibition of human HT-29 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human HT-29 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
IGROV-1	GI₅₀	0.388 μM Compound: 5, NSC-747259	Growth inhibition of human IGROV1 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human IGROV1 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
K562	GI₅₀	0.186 μM Compound: 5, NSC-747259	Growth inhibition of human K562 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human K562 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
KM12	GI₅₀	0.31 μM Compound: 5, NSC-747259	Growth inhibition of human KM12 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human KM12 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
LOX IMVI	GI₅₀	0.192 μM Compound: 5, NSC-747259	Growth inhibition of human LOXIMVI cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human LOXIMVI cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
M14	GI₅₀	0.453 μM Compound: 5, NSC-747259	Growth inhibition of human M14 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human M14 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
Malme-3M	GI₅₀	0.29 μM Compound: 5, NSC-747259	Growth inhibition of human MALME-3M cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human MALME-3M cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
MCF7	GI₅₀	0.317 μM Compound: 5, NSC-747259	Growth inhibition of human MCF7 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human MCF7 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
MDA-MB-231	GI₅₀	0.345 μM Compound: 5, NSC-747259	Growth inhibition of human MDA-MB-231 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human MDA-MB-231 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
MDA-MB-435	GI₅₀	0.335 μM Compound: 5, NSC-747259	Growth inhibition of human MDA-MB-435 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human MDA-MB-435 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
MDA-MB-468	GI₅₀	0.119 μM Compound: 5, NSC-747259	Growth inhibition of human MDA-MB-468 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human MDA-MB-468 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
MOLT-4	GI₅₀	0.324 μM Compound: 5, NSC-747259	Growth inhibition of human MOLT4 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human MOLT4 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
NCI/ADR-RES	GI₅₀	1.68 μM Compound: 5, NSC-747259	Growth inhibition of human NCI/ADR-RES cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human NCI/ADR-RES cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
NCI-H226	GI₅₀	0.478 μM Compound: 5, NSC-747259	Growth inhibition of human NCI-H226 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human NCI-H226 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
NCI-H23	GI₅₀	0.308 μM Compound: 5, NSC-747259	Growth inhibition of human NCI-H23 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human NCI-H23 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
NCI-H322M	GI₅₀	1.81 μM Compound: 5, NSC-747259	Growth inhibition of human NCI-H322M cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human NCI-H322M cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
NCI-H460	GI₅₀	0.362 μM Compound: 5, NSC-747259	Growth inhibition of human NCI-H460 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human NCI-H460 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
NCI-H522	GI₅₀	0.287 μM Compound: 5, NSC-747259	Growth inhibition of human NCI-H522 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human NCI-H522 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
OVCAR-3	GI₅₀	0.315 μM Compound: 5, NSC-747259	Growth inhibition of human OVCAR-3 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human OVCAR-3 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
OVCAR-4	GI₅₀	0.309 μM Compound: 5, NSC-747259	Growth inhibition of human OVCAR4 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human OVCAR4 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
OVCAR-5	GI₅₀	1.24 μM Compound: 5, NSC-747259	Growth inhibition of human OVCAR5 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human OVCAR5 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
OVCAR-8	GI₅₀	0.468 μM Compound: 5, NSC-747259	Growth inhibition of human OVCAR8 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human OVCAR8 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
PC-3	GI₅₀	0.282 μM Compound: 5, NSC-747259	Growth inhibition of human PC3 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human PC3 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
RPMI-8226	GI₅₀	0.046 μM Compound: 5, NSC-747259	Growth inhibition of human RPMI8226 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human RPMI8226 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
RXF 393	GI₅₀	0.464 μM Compound: 5, NSC-747259	Growth inhibition of human RFX393 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human RFX393 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SF-268	GI₅₀	0.493 μM Compound: 5, NSC-747259	Growth inhibition of human SF268 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SF268 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SF-295	GI₅₀	0.333 μM Compound: 5, NSC-747259	Growth inhibition of human SF295 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SF295 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SF-539	GI₅₀	0.514 μM Compound: 5, NSC-747259	Growth inhibition of human SF539 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SF539 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SK-MEL-2	GI₅₀	0.356 μM Compound: 5, NSC-747259	Growth inhibition of human SK-MEL-2 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SK-MEL-2 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SK-MEL-28	GI₅₀	0.71 μM Compound: 5, NSC-747259	Growth inhibition of human SK-MEL-28 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SK-MEL-28 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SK-MEL-5	GI₅₀	0.177 μM Compound: 5, NSC-747259	Growth inhibition of human SK-MEL-5 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SK-MEL-5 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SK-OV-3	GI₅₀	0.565 μM Compound: 5, NSC-747259	Growth inhibition of human SKOV3 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SKOV3 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SN12C	GI₅₀	0.367 μM Compound: 5, NSC-747259	Growth inhibition of human SN12C cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SN12C cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SNB-19	GI₅₀	0.587 μM Compound: 5, NSC-747259	Growth inhibition of human SNB19 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SNB19 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SNB-75	GI₅₀	0.336 μM Compound: 5, NSC-747259	Growth inhibition of human SNB75 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SNB75 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SR	GI₅₀	0.162 μM Compound: 5, NSC-747259	Growth inhibition of human SR cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SR cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
SW-620	GI₅₀	0.378 μM Compound: 5, NSC-747259	Growth inhibition of human SW620 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human SW620 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
T47D	GI₅₀	0.428 μM Compound: 5, NSC-747259	Growth inhibition of human T47D cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human T47D cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
TK-10	GI₅₀	0.503 μM Compound: 5, NSC-747259	Growth inhibition of human TK10 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human TK10 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
U-251	GI₅₀	0.334 μM Compound: 5, NSC-747259	Growth inhibition of human U251 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human U251 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
UACC-257	GI₅₀	0.411 μM Compound: 5, NSC-747259	Growth inhibition of human UACC257 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human UACC257 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
UACC-62	GI₅₀	0.335 μM Compound: 5, NSC-747259	Growth inhibition of human UACC62 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human UACC62 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]
UO-31	GI₅₀	0.686 μM Compound: 5, NSC-747259	Growth inhibition of human UO31 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control Growth inhibition of human UO31 cells assessed as drug level required for 50% reduction in net protein increase by SRB assay relative to control	[PMID: 19615902]

Chemical Information

CAS. Nr. 375395-33-8
Appearance Viscous Liquid
Molecular Weight 648.85
Formel C₂₇H₅₄F₆N₂O₄S₂
Color Colorless to light yellow
SMILES

CCCCCCCC[N+](CCCCCCCC)(C)CCCCCCCC.O=S([N-]S(=O)(C(F)(F)F)=O)(C(F)(F)F)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (262 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Yamato K, et al. Stability of electrochemomechanical strains in polypyrrole films using ionic liquids. Synthetic metals, 2009, 159(9-10): 839-842.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge: